ImmunoGen Inc to Discuss Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer Call
שיחת ועידה ImmunoGen Inc
ImmunoGen Inc Conference call or earnings call will be held on 17/12/2019 via an 800 number (toll-free). During the earnings conference call's session ImmunoGen Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact ImmunoGen Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies, highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream and released in their fully active form after delivery to a cancer cell. An anticancer compound made using our Targeted Antibody Payload, or TAP, technology consists of a monoclonal antibody that binds specifically to an antigen target found on cancer cells with multiple copies of one of our proprietary cell-killing agents attached using one of our engineered linkers. Its antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen, the highly potent cytotoxic agent serves to kill the cancer cell, and the engineered linker controls the release and activation of the cytotoxic agent inside the cancer cell.קרא עוד שיחת ועידה